Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Neurocrine Biosciences (NBIX) Return on Equity (2016 - 2025)

Neurocrine Biosciences (NBIX) has disclosed Return on Equity for 14 consecutive years, with 0.15% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Return on Equity rose 2.0% year-over-year to 0.15%, compared with a TTM value of 0.15% through Dec 2025, up 2.0%, and an annual FY2025 reading of 0.16%, up 2.0% over the prior year.
  • Return on Equity was 0.15% for Q4 2025 at Neurocrine Biosciences, up from 0.15% in the prior quarter.
  • Across five years, Return on Equity topped out at 0.17% in Q1 2024 and bottomed at 0.01% in Q2 2021.
  • Average Return on Equity over 4 years is 0.1%, with a median of 0.12% recorded in 2023.
  • The sharpest move saw Return on Equity dropped -28bps in 2021, then increased 15bps in 2024.
  • Year by year, Return on Equity stood at 0.08% in 2021, then skyrocketed by 55bps to 0.12% in 2023, then rose by 4bps to 0.13% in 2024, then rose by 19bps to 0.15% in 2025.
  • Business Quant data shows Return on Equity for NBIX at 0.15% in Q4 2025, 0.15% in Q3 2025, and 0.13% in Q2 2025.